By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Glycobiosciences,
Inc. v. Anika Therapeutics, Inc.
1:12-cv-01963;
filed November 25, 2012 in the District Court of the District of Columbia

Infringement
of U.S. Patent Nos. 6,120,804 ("Topical Drug Preparations," issued
September 19, 2000) and 6,723,345 (same title, issued April 20, 2004) based on
Anika's manufacture, use, offer for sale, and sale of their Hyalofill® product
(wound dressings composed of an ester of hyaluronic acid, used to treat
wounds).  View the complaint here.

Cellectis
S.A. v. Precision Biosciences Inc. et al.
1:12-cv-01662;
filed December 5, 2012 in the District Court of Delaware

• Plaintiff: 
Cellectis S.A.
• Defendants: 
Precision Biosciences Inc.; Duke University

Declaratory
judgment of invalidity and non-infringement of U.S. Patent No. 8,304,222 ("Rationally-Designed
Meganucleases with Altered Sequence Specificity and Heterodimer Formation,"
issued November 6, 2012).  View the
complaint here.

Medicis
Pharmaceutical Corp. v. Alkem Laboratories Ltd. et al.
1:12-cv-01663;
filed December 5, 2012 in the District Court of Delaware

• Plaintiff: 
Medicis Pharmaceutical Corp.
• Defendants: 
Alkem Laboratories Ltd.; Pharma Network LLC; Ascend Laboratories LLC

Medicis
Pharmaceutical Corp. v. Sidmak Laboratories (India) Pvt. Ltd.
1:12-cv-01664;
filed December 5, 2012 in the District Court of Delaware

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 5,908,838 ("Method
for the Treatment of Acne," issued June 1, 1999), 7,790,705 ("Minocycline
Oral Dosage Forms for the Treatment of Acne," issued September 7, 2010),
and 8,268,804 (same title, issued September 18, 2012) following a Paragraph IV
certification as part of defendants' filing of an ANDA to manufacture a generic
version of Medics' Solodyn® (minocycline hydrochloride extended release
tablets, used to treat acne).  View the Alkem complaint here.

Merial
Limited et al. v. Ceva Animal Health LLC
3:12-cv-00154;
filed December 5, 2012 in the Middle District of Georgia

• Plaintiffs: 
Merial Ltd.; Merial SAS
• Defendant: 
Ceva Animal Health LLC

Infringement
of U.S. Patent No. 6,096,329 ("Insecticidal Combination to Control Mammal
Fleas, in Particular Fleas on Cats and Dogs," issued August 1, 2000),
licensed to Merial in the animal health field, based on Ceva's manufacture and impending
sale of infringing flea and tick products. 
View the complaint here.

Jazz
Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.
2:12-cv-07459;
filed December 5, 2012 in the District Court of New Jersey

Infringement
of U.S. Patent No. 8,324,275 (" Microbiologically Sound and Stable
Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy,"  issued December 4, 2012) following a
Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture
a generic version of Jazz's Xyrem® (sodium oxybate, used to treat
narcolepsy).  View the complaint here.

Supernus
Pharmaceuticals, Inc. v. Kappos
1:12-cv-01385;
filed November 30, 2012 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,193,211 ("Controlled Release
Compositions of Gamma-Hydroxybutyrate," issued June 5, 2012).  View the complaint here.

Bayer Pharma
AG et al. v. Lupin Ltd. et al.
1:12-cv-03526;
filed November 29, 2012 in the District Court of Maryland

• Plaintiffs: 
Bayer Pharma AG; Bayer Intellectual Property GmbH; Bayer Healthcare
Pharmaceuticals Inc.
• Defendants: 
Lupin Ltd.; Lupin Pharmaceuticals, Inc.

Infringement
of U.S. Patent No. 8,071,577 ("Multi-phase Contraceptive Preparation Based
On a Natural Estrogen," issued December 6, 2011) following a Paragraph IV
certification as part of Lupin's filing of an ANDA to manufacture a generic
version of Bayer's Natazia® (estradiol valerate and estradiol
valerate/dienogest, used as oral contraception).  View the complaint here.